secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001104659-22-114895
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech receives Nasdaq bid price deficiency notice; 180-day cure period through May 1, 2023
--------------------------------------------------------------------------------

- Received Nasdaq letter on Oct 31, 2022 for bid price below $1.00 for 30 consecutive business days.
- Non-compliance with Nasdaq Listing Rule 5550(a)(2) for common stock (FBIO).
- 180-day grace period through May 1, 2023; must close at $1.00+ for 10 consecutive days to cure.
- If not cured, may be eligible for another 180 days if meets initial listing criteria and market value requirement.
- Company evaluating options to remedy bid price deficiency; no decision made yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465922114895/0001104659-22-114895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465922114895/tm2229531-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer